SIRPA and neoplasm: constructed 4T1 tumor CMs with highly expressed CD47 by gene transfection utilizing lentivirus plasmid in 4T1 cells, thus blocking the phagocytosis by macrophages and enhancing homologous targeting capacities by tumor cells through the combination of CD47 with signal regulatory protein alpha.[55] Particularly, the gene‐edited chimeric antigen receptor (CAR) T‐CMs have been designed to express targeting molecule or single‐chain variable fragment (Figure 3C), paving the path for tumor‐targeted therapies.[56]